Home › IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal

IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal

Mar 08, 2017

NEW YORK (GenomeWeb) — IntegraGen announced today that it has signed an agreement giving Laboratoire Cerba the right to develop a tumor expression test based on its microRNA biomarker miR-31-3p.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Cancer

  1. Cancer Genetics Cancels Planned Merger With NovellusDx

  2. Black Women With Breast Cancer Fare Worse, TAILORx Analysis Confirms at SABCS

    Premium

  3. Synlab Pharma, Biotype Collaborate on Gastrointestinal, Endometrial Cancers

  4. Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs

  5. Live Cell Phenotyping Test Predicts Prostate Cancer Pathology with High Precision

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.